Sibrafiban is an orally bioavailable non-peptide GPIIb/IIIa antagonist, under development by Genentech and Hoffmann-La Roche, and in phase III trials as an antithrombotic. References: Wong CK, Newby LK, Bhapker MV, Aylward PE, Pfisterer M, Alexander KP, Armstrong PW, Hochman JS, Van de Werf F, Califf RM, White HD; SYMPHONY and 2nd SYMPHONY Investigators.. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. Am Heart J. 2007 Aug;154(2):313-21. PubMed PMID: 17643582.

纯度：≥98%

CAS：170094-62-9